Responses to immunizations in rheumatoid arthritis patients treated with a cd20 antibody
AssigneeGenentech, Inc.
InventorsAriella Kelman, Benjamin L. Trzaskoma
Life of this patent
Estimating the term…
Abstract
The present invention provides clinical data evaluating the efficacy of responses to immunizations in rheumatoid arthritis (RA) patients treated with a CD20 antibody.
Claims32
A method of treating a human rheumatoid arthritis (RA) patient comprising administering to the patient:
- (a) a CD20 antibody in an amount effective to treat the RA, and (b) a protein vaccine in an amount effective to mount a memory immune response to the protein vaccine.
A method of mounting a 4-fold increase in anti-protein titer in a human rheumatoid arthritis (RA) patient following vaccination with a protein vaccine, comprising administering the protein vaccine to a RA patient who has been treated with a CD20 antibody, and measuring the 4-fold increase in anti-protein titer in the patient.
A method of treating human patients having rheumatoid arthritis (RA) comprising treating a first group of the RA patients with a CD20 antibody, methotrexate, and a protein vaccine, and treating a second group of the RA patients with methotrexate and the protein vaccine but not the CD20 antibody, and determining that memory immune responses raised by the first and second groups of patients are about the same.
A method for advertising a CD20 antibody comprising promoting the use of the CD20 antibody for treating a human rheumatoid arthritis (RA) patient, wherein the RA patient is able to mount an effective memory immune response to a protein vaccine administered following administration of the CD20 antibody.
A method of providing a pharmaceutical composition for treating a human rheumatoid arthritis (RA) patient, comprising combining a container holding a pharmaceutically acceptable composition comprising a CD20 antibody with a package insert, wherein the package insert promotes the use of the composition to treat a RA patient who is able to mount an effective memory immune response to a protein vaccine administered following administration of the CD20 antibody.
Dependencies are inferred from the claim text.